Skip to main content

Collagenase Santyl Side Effects

Generic name: collagenase topical

Medically reviewed by Drugs.com. Last updated on Dec 12, 2023.

Note: This document contains side effect information about collagenase topical. Some dosage forms listed on this page may not apply to the brand name Collagenase Santyl.

Applies to collagenase topical: topical application ointment.

Serious side effects of Collagenase Santyl

Along with its needed effects, collagenase topical (the active ingredient contained in Collagenase Santyl) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking collagenase topical:

Incidence not known

Other side effects of Collagenase Santyl

Some side effects of collagenase topical may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

For Healthcare Professionals

Applies to collagenase topical: compounding powder, topical ointment.

General

The most commonly reported side effect was erythema.[Ref]

Hypersensitivity

Frequency not reported: Systemic manifestations of hypersensitivity (in a patient treated for more than one year with a combination of collagenase and cortisone)[Ref]

Dermatologic

Frequency not reported: Erythema[Ref]

References

1. Product Information. Santyl (collagenase topical). Knoll Pharmaceutical Company. 2002.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.